1 The penetrance of rare variants in cardiomyopathy-associated genes: 2 a cross-sectional approach to estimate penetrance for secondary findings

Kathryn A. McGurk^{1,2}, Xiaolei Zhang^{1,15}, Pantazis Theotokis^{1,2}, Kate Thomson⁴, Andrew Harper^{4,16}, Rachel J. Buchan^{1,2,3}, Erica Mazaika¹, Elizabeth Ormondroyd⁴, William T. Wright⁵, Daniela Macaya⁶, Chee Jian Pua⁷, Birgit Funke⁸, Daniel G. MacArthur^{9,10}, Sanjay Prasad^{1,3}, Stuart A. Cook^{2,7}, Mona Allouba^{1,11}, Yasmine Aguib^{1,11}, Magdi H. Yacoub^{1,3,11}, Declan P. O'Regan², Paul J. R. Barton^{1,2,3}, Hugh Watkins⁴, Leonardo Bottolo^{12,13,14}, James S. Ware^{1,2,3,*}.

9

¹National Heart and Lung Institute, Imperial College London, London, UK.

- ²MRC London Institute of Medical Sciences, Imperial College London, London, UK.
- ³Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust,
- 13 London, UK.
- ⁴Division of Cardiovascular Medicine, Radcliffe Department of Medicine and the
- 15 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
- ⁵Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust,
- 17 Belfast City Hospital, Belfast, Northern Ireland, UK.
- ⁶GeneDx LLC, Gaithersburg, Maryland, US.
- ⁷National Heart Research Institute Singapore and Duke-National University of
- 20 Singapore, Singapore.
- ⁸Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized
- 22 Genetic Medicine, Boston, Massachusetts, USA.
- ⁹Centre for Population Genomics, Garvan Institute of Medical Research and UNSW,
- 24 Sydney, NSW, Australia.
- ¹⁰Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne,
- 26 VIC, Australia.
- 27 ¹¹Aswan Heart Centre, Aswan, Egypt.
- ¹²Department of Medical Genetics, University of Cambridge, Cambridge, UK.
- ¹³The Alan Turing Institute, London, UK.
- ¹⁴MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
- ¹⁵Current address: European Bioinformatics Institute, Wellcome Genome Campus,
- 32 Hinxton, UK.
- ¹⁶Current address: Centre for Genomics Research, Discovery Sciences,
- 34 BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- 35
- 36 ***Corresponding author:** Professor James S. Ware, j.ware@imperial.ac.uk
- 37 Word count: 5,499
- 38 **Keywords:** Penetrance, Cardiomyopathy, Prevalence, Secondary findings

39 Abstract

Understanding the penetrance of pathogenic variants identified as secondary findings 40 41 (SFs) is of paramount importance with the growing availability of genetic testing. We 42 estimated penetrance through large-scale analyses of patients referred for diagnostic 43 sequencing for hypertrophic cardiomyopathy (HCM; 10,400 cases, 1,340 variants) and dilated cardiomyopathy (DCM; 2,564 cases, 665 variants), using a cross-sectional 44 45 approach comparing allele frequencies against reference populations (293,226 46 participants from UK Biobank and gnomAD). We generated updated prevalence 47 estimates for HCM (1:543) and DCM (1:220).

In aggregate, the penetrance by late adulthood of rare, pathogenic variants (23% for HCM, 35% for DCM) and likely pathogenic variants (7% for HCM, 10% for DCM) was substantial for dominant CM. Penetrance was significantly higher for variant subgroups annotated as loss of function or ultra-rare, and for males compared to females for variants in HCM-associated genes.

53 We estimated variant-specific penetrance for 316 recurrent variants most likely to be 54 identified as SFs (51% HCM and 17% DCM cases). 49 variants were observed at least 55 ten times (14% of cases) in HCM-associated genes. Median penetrance was 14.6% 56 (±14.4% SD). We explore estimates of penetrance by age, sex, and ancestry, and 57 simulate the impact of including future cohorts.

58 This dataset is the first to report penetrance of individual variants at scale and will 59 inform the management of individuals undergoing genetic screening for SFs. While 60 most variants had low penetrance and the costs and harms of screening are unclear, 61 some carriers of highly penetrant variants may benefit from SFs.

62

63 Graphical Abstract

A flowchart of the estimated penetrance for dominant cardiomyopathy by late adulthood 64 65 for a variant of interest. The estimates of penetrance in this study are for carriers 66 identified from unselected populations (e.g., consumer-initiated elective genomic testing 67 or as secondary (2°) findings in clinical settings). If the variant is ultra-rare (i.e., 68 identified once or less in population datasets), only estimates by variant subgroup in 69 aggregate are available. If the variant is identified multiple times in both case and 70 population datasets, variant-specific penetrance estimates may be available. If the 71 variant is curated as a variant of uncertain significance (VUS), the penetrance estimate 72 is low. If the variant is a likely pathogenic predicted loss of function (pLoF) variant and is 73 identifiable multiple times in cases and population cohorts, penetrance estimates vary 74 by gene (Figure 2). High aggregate penetrance represents an estimate of >25%; 75 moderate aggregate penetrance represents 10%-25%, and low penetrance represents 76 <10%. This flowchart was created with draw.io.

77 Introduction

78 Cardiomyopathies (CM) are diseases of the heart muscle, characterised by abnormal 79 cardiac structure and function that is not due to coronary disease, hypertension, valve 80 disease, or congenital heart disease. Many cases have a monogenic etiology with 81 autosomal dominant inheritance. Penetrance is incomplete and age-related, and 82 expressivity is highly variable. These features present huge challenges for disease 83 management. In particular, the penetrance of variants in CM-associated genes is 84 incompletely characterised and poorly understood, especially when identified in an 85 asymptomatic individual without family history of CM. With the growing availability of 86 whole exome sequencing in wider clinical settings and consumer-initiated elective 87 genomic testing¹, the importance of estimating the penetrance of individual variants 88 identified as secondary findings (SFs) to guide intervention is ever-increasing.

89 SFs are genetic variants that are actively sought out (as opposed to incidental findings). 90 but which are unrelated to the clinical indication for genetic testing and can therefore be 91 considered as opportunistic genetic screening. Genes associated with inherited CMs 92 make up one-fifth of the 78 genes recommended by the American College of Medical 93 Genetics and Genomics (ACMG SF v3.1) for reporting SFs during clinical sequencing². 94 It is recommended to return variants that would be classified as pathogenic or likely 95 pathogenic in an affected individual and where there is >90% confidence that the variant is causing the observed disease³. This is independent of the probability that an 96 97 individual carrying the variant will develop disease (penetrance). The ACMG SF 98 guidelines have not yet been adopted globally, with the European Society of Human 99 Genetics recommending a cautious approach with limited capacity, but responsive to 100 accumulating evidence^{4,5}.

101 We are concerned that the costs, harms, and benefits, have not been fully 102 characterised. We have previously discussed issues with the recommendations based 103 on the lack of estimates of the harms and cost of this approach for variants in specific 104 genes⁶. These estimates are required to conform to the ninth rule of Wilson and 105 Jugner's principles of screening⁷. The burden of the implementation of reporting SFs in 106 specific healthcare systems remains unassessed. There is little evidence for clinical utility and limited justification for use of resources⁵. Research is beginning to become 107 108 available on patient perspectives and impact⁸⁻¹².

109 Subclinical phenotypic expressivity of rare variants in CM-associated genes has been demonstrated in the UK Biobank population cohort¹³⁻¹⁵. Causes of variability in 110 111 penetrance may include: i) genetic and allelic heterogeneity, with different alleles having 112 different consequences on protein function, ii) environmental modifiers altering genetic 113 influence (e.g., age, sex, hypertension, lifestyle), and iii) additional genetic modifiers 114 with additive or epistatic interactions with the variant of interest (other variants or 115 combinations of genetic factors, e.g. polygenic risk, variants in *cis* that drive allelic 116 imbalance, imprinting, epigenetic regulation, compensation, threshold model, and transcript isoform expression)¹⁶⁻²². 117

118 Variant-specific estimates of penetrance are required to appropriately inform clinical 119 practice and to fully utilise genetics as a tool to individualise the risk of developing disease in asymptomatic carriers^{6,23}. It is challenging to estimate the penetrance of 120 individual rare variants through other study methods as longitudinal population studies 121 122 require very large sample sizes and long-term follow-up is required if penetrance is age-123 related. Where data is available for rare variants in CM-associated genes, reported 124 penetrance is mostly estimated from family-based studies. These may be affected by ascertainment biases and secondary genetic and environmental factors²⁴ and thus less 125 applicable to SFs. Penetrance has been estimated in aggregate by gene and by 126 disease^{13,25,26}. Variant-specific penetrance in the general adult population for rare 127 variants in CM-associated genes is unknown. 128

Here, we apply a cross-sectional approach, using a method that compares the allele frequency of individual rare variants in large cohorts of cases and reference populations to estimate penetrance. As well as providing aggregated penetrance estimates for groups of rare variants (e.g., those curated as pathogenic), this approach can estimate the penetrance of *individual* rare alleles. Importantly, these estimates represent variants in the general population, rather than in families ascertained for disease.

135 Methods

136 Case cohort

137 Sequencing data for 10,400 individuals referred for HCM gene panel sequencing, and 138 2,564 individuals referred for DCM gene panel sequencing was collected from seven 139 international testing centres: three UK-based - the NIHR Royal Brompton Biobank, 140 Oxford Molecular Genetics Laboratory, and Belfast Regional Genetics Laboratory; two 141 US-based - the Partners Laboratory of Molecular Medicine and GeneDx; and the 142 National Heart Centre, Singapore, and Aswan Heart Centre, Egypt. Although the diagnosis cannot directly be reconfirmed, given genetic testing guidelines (e.g., 3,27), a 143 144 clinical diagnosis of CM is implicit. For information on DNA sequencing and data 145 obtained for analyses, see the supplementary materials.

For each variant observed in one or more individuals referred for CM sequencing, we calculated the allele count (AC) and allele number (AN), and further stratified by reported age, sex, and ancestry, where the data allowed. All patients gave written informed consent, and the study was approved by the relevant regional research ethics committees.

151 Population cohort

167,478 participants of the UK Biobank (UKBB) with whole exome sequencing data
available for analyses and 125,748 exome sequenced participants of the Genome
Aggregation Database (gnomAD; version v2.1.1) were included in this study.

155 Briefly, the UK Biobank recruited participants aged 40–69 years old from across the UK between 2006 and 2010²⁸, of which the 200.571 exome tranche of individuals that had 156 not withdrawn, were included in this study²⁹. The maximal subset of unrelated 157 participants was used, identified by those included in the UKBB PCA analysis (S3.3.2²⁸, 158 159 n=167,478). Age at recruitment, genetic sex, and genetic (for European (EUR) and 160 British ancestry) or reported ancestry information (for other global ancestries: AFR, 161 African, Caribbean (n=2,903); SAS, Indian, Pakistani, Bangladeshi (n=3,136); EAS, 162 Chinese (n=605)) were incorporated.

163 The gnomAD database contains sequencing information for unrelated individuals 164 sequenced as part of various disease-specific and population genetic studies³⁰. The 165 version 2 short variant dataset spans 125,748 exomes from unrelated individuals 166 sequenced as part of various disease-specific and population genetic studies. Ensembl Variant Effect Predictor³¹ (VEP, version 105) was used to incorporate the variant-167 168 specific summary counts. Variants flagged by gnomAD as AC0 were excluded from 169 gnomAD counts. For more information on the incorporation of these datasets, please see the supplementary materials. 170

171 Variant annotation

VEP (105) was used to annotate the case and population datasets, with additional plugins: gnomAD³⁰ (version r2.1), LOFTEE³⁰, SpliceAl³² (1.3.1), REVEL³³ (1.3), and

174 ClinVar³⁴ (20220115). The data was organised using PLINK³⁵ (1.9) and the VEP output 175 was analysed using R (4.1.2).

176 Protein altering variants, defined with respect to MANE transcripts, that were annotated as high or moderate impact by SO and ENSEMBL were included in the analysis. 177 Analysis was restricted to genes with strong or definitive evidence of causing CM 178 following ClinGen guidance^{36,37} and expert curation (gene2phenotype Cardiac Panel; 179 180 https://www.ebi.ac.uk/gene2phenotype/), to include 8 sarcomeric HCM-associated 181 genes (MYH7, MYBPC3, MYL2, MYL3, ACTC1, TNNI3, TNNT2, TPM1) and 11 DCM-182 associated genes (BAG3, DES, DSP, LMNA, MYH7, PLN, RBM20, SCN5A, TNNC1, 183 TNNT2, $TTN_{PSI>90\%}$), with the exception of FLNC that was not included on the panel 184 sequencing of the DCM case cohort (**Table S4**). Variants with consequences consistent with the known disease-causing mechanism were retained. 185

186 Further manual annotation was undertaken following ACMG guidelines using ClinVar³⁴

187 and Cardioclassifier³⁸, as previously published¹³. For analyses of variants in aggregate,

188 the UKBB data was filtered following the same thresholds and used to estimate 189 aggregate penetrance.

- 190 Statistical analysis
- 191 Estimation of penetrance and 95% confidence interval
- 192 Penetrance is expressed as a probability function on a scale of 0%-100%. Penetrance
- 193 was estimated from case-population data in a Binomial framework following Bayes'
- 194 theorem for conditional probability²⁶

$$P(D|A) = P(D) \frac{P(A|D)}{P(A)},$$

penetrance = population prevalence $\frac{\text{case allele frequency}}{\text{population allele frequency'}}$

195 where, *D*, disease; *A*, allele; and P, probability, P(D|A) = penetrance (probability of 196 disease given a risk allele), P(D) = fixed population baseline risk of disease (probability 197 of disease), P(A|D) = allele frequency in the case cohort (probability of the allele given 198 disease), P(A) = allele frequency in the population cohort (probability of the allele).

199 We define penetrance in this setting as the probability of dominant CM by late adulthood 200 (UKBB had a mean age of 56 years old at recruitment). We assume the independence 201 of the random variables in the penetrance equation above to derive the 95% confidence 202 interval for penetrance as the product and ratio of binomial proportions. We used the 203 specialised version of the Central Limit Theorem, the Delta method, on the log-204 transformed random variable $\log(D|A) = \log(D) + \log(A|D) - \log(A)$ with an improved 205 mean approximation and adjustment for degeneracy (as allele frequency tends to 0 for 206 rare variants). Please see additional methods and alternative approaches considered 207 (Supplementary methods, Table S3, Lists S1-S2, Figures S4-S5).

- For estimates of penetrance by sex, we adjusted all terms of the penetrance equation by values for sex-specific parameters. For estimates of penetrance by ancestry, we kept P(D) as estimated for CM (there are few estimates of the prevalence of CM in specific ancestries) and proportioned P(A|D) and P(A) by reported ancestry. For estimates of penetrance by age, we normalised P(D) by the number diagnosed in the case cohort by a particular age in a cumulative fashion, with P(A|D) by a particular age, and P(A) fixed as total population allele frequency (**Supplementary methods**).
- 215 Estimated cardiomyopathy prevalence

216 To incorporate P(D) in our penetrance analysis, we estimated the uncertainty surrounding the reported prevalence of CM (Tables S1-S2, Figures S1-S3). For HCM, 217 we meta-analysed four imaging-based prevalence estimates^{13,39-41} excluding studies 218 with potential selection biases. From the meta-analysis estimate $(p_D \equiv P(D))$ and its 219 confidence interval, we derived values of allele count, x_D , and allele number, n_D (where 220 $p = \frac{x}{x}$). A literature review was also completed for DCM, but there were not enough 221 imaging-based prevalence estimates in literature, so 39,003 participants of the UK 222 Biobank imaging cohort were used to estimate phenotypic DCM⁴²⁻⁴⁴ (Supplementary 223 224 methods). Using the same methods and included studies, we derived estimates for 225 male- and female-specific HCM and DCM prevalence.

226 Results

227 Case cohort summary information

228 Sequencing data for 10,400 individuals referred for HCM genetic panel sequencing and 229 2,564 individuals referred for DCM genetic panel sequencing were included in the 230 analysis. Aggregated frequency of rare protein altering variants in well-established 231 disease genes was 42% for HCM and 33% for DCM in the respective case cohorts 232 (Tables S6-S7). Of the cohorts with age, sex, and ancestry information available (20%) of HCM cases, 42% of DCM cases), 35% and 32% were female, 93% and 91% were of 233 234 EUR ancestry, and mean age was 48 and 49 years old, for HCM and DCM, respectively 235 (Table S5).

236 New estimates of the prevalence of cardiomyopathies

237 To estimate the prevalence of CMs, a literature review and meta-analysis were 238 undertaken (Tables S1-S2, Figures S1-S3). Prevalence is underestimated when 239 derived from national cohorts using coding systems such as ICD codes, due to incomplete ascertainment through diagnostic and procedure coding⁴⁵. We would 240 therefore expect the most accurate estimates of the prevalence of CM to come from 241 242 imaging studies in populations, where echocardiogram or cardiac magnetic resonance 243 imaging was used to identify CM within a population sample that is representative. The 244 estimates are not generalisable if the prevalence is estimated for selected subgroups of 245 individuals, such as young, elderly, or athletic cohorts. We therefore meta-analysed four imaging-based prevalence estimates which resulted in a HCM population prevalence 246 estimate of 1 in 543 individuals ($p_D = 0.18\%$ (95% CI_D = 0.15%-0.23%))^{13,39-41}. The well 247 reported estimate of 1 in 500 individuals for HCM prevalence (0.20%) is within this 248 confidence interval. 249

A literature review revealed insufficient imaging-based estimates to undertake a direct meta-analysis of the prevalence of DCM. Instead, we used 39,003 participants of the UK Biobank imaging cohort to estimate phenotypic DCM⁴²⁻⁴⁴. This derived a DCM population prevalence of 1 in 220 individuals ($p_D = 0.45\%$ (95% CI_D = 0.39%-0.53%)), which includes the well reported estimate of 1 in 250 (0.40%)⁴⁶ within the confidence interval.

We also estimated sex-specific CM prevalence. This resulted in a HCM population prevalence of ~1 in 1,300 females ($p_D = 0.08\%$ (95% CI_D = 0.04%-0.12%)) and ~1 in 360 males ($p_D = 0.28\%$ (95% CI_D = 0.22%-0.35%)), and a DCM population prevalence of ~1 in 340 females ($p_D = 0.30\%$ (95% CI_D = 0.23%-0.38%)) and ~1 in 160 males ($p_D = 0.63\%$ (95% CI_D = 0.52%-0.75%)).

261 *Estimated penetrance of rare variants in aggregate*

In individuals with cardiomyopathy referred for diagnostic sequencing, we identified 1,340 rare (inclusive population allele frequency of <0.1%) variants in HCM-associated genes (4,314 observations, case frequency 42%) and 665 rare variants in DCM-

associated genes (833 observations, case frequency 33%) (Tables S6-S9). The UKBB
dataset was filtered following the same pipeline. 1,735 rare variants in HCM-associated
genes (9,196 observations, 5.5% population frequency) and 4,586 rare variants in
DCM-associated genes (22,232 observations; 13.3% population frequency) were used
to estimate aggregate penetrance of rare variant subgroups. Variants with a pathogenic
classification in ClinVar were the most penetrant subgroup by ACMG classification⁴⁵
(HCM 22.5% (17.5%-28.8%), DCM 35.0% (21.6%-56.8%); Figure 1, Table S15).

272

An estimate of the aggregate penetrance of both pathogenic and likely pathogenic variants in HCM was 10.7% (8.6%-13.3%) using this approach, concordant to a recent estimate derived using direct assessment of cardiac imaging in UKBB (10.8%; variant carriers with LVH \geq 13mm without hypertension or valve disease; binomial 95% confidence interval of 3.0%-25.4%; n=4/37)¹¹. This concordance was also observed for other variants in the same paper (e.g., VUS) which we estimated penetrance as 0.55% (0.45%-0.68%) compared to 0.57% (0.07%-2.03%, n=2/353)¹¹.

280

The aggregate penetrance of pathogenic and likely pathogenic variants in DCM was 11.3% (9.3%-13.6%). Population penetrance of rare variants in DCM-associated genes in UKBB has previously been estimated at $\leq 30\%^{47}$ for a clinical or subclinical diagnosis in an analysis of 44 DCM-associated genes, and in the range of 5%-6% for TTNtvs (1.9%-12.8%; 877 carriers)⁶ depending on the definition used. We report a concordant penetrance estimate from our analysis of strong- and definitive-evidence DCM genes only, and 9.8% (8.0%-12.1%) for TTNtvs (**Figure 2, Figure S12**).

Variants predicted to result in premature termination codons (PTCs; nonsense mediated decay competent or incompetent⁴⁸) in *MYBPC3, BAG3, DSP,* and *LMNA*, were the most penetrant (Figure 2, Figure S12, Tables S13-S14, Tables S18-S19). Inframe deletions in *TNNT2* were highly penetrant for both HCM and DCM. TTNtvs and missense variants predicted to be damaging in *TPM1* and *TNNC1*, had moderate penetrance.

- 295 Stratification by variant rarity showed that variants absent from the gnomAD database 296 were the most penetrant subgroup (HCM pathogenic 91.9% (57.3%-100.0%), HCM 297 likely pathogenic 20.2% (14.2%-28.7%2), DCM pathogenic 100.0% (56.3%-100.0%), 298 DCM likely pathogenic 13.7% (11.2%-16.8%); Figure 1, Table S16). Stratification of 299 penetrance by sex identified increased penetrance for males compared to females for 300 rare variants in HCM-associated genes (Figure 1, Figure S13, Table S20). Penetrance 301 was estimated as <20% up to 50 years of age by modelling the penetrance of CM as an 302 age-related cumulative frequency using the proportion of cases referred at each age 303 decile (Figure 1, Table S17).
- 304

While there are limitations to the cohort size when split by reported ancestry and we are unable to rule out local ancestry mismatches between case and population datasets, there was no significant difference in the penetrance of truncating variants in *TTN* (TTNtvs_{PSI>90%}) between African (5.7% (2.9%-10.9%)), European (6.9% (5.5-8.5%)), East Asian (6.1% (3.0%-12.4%)), and South Asian (5.7% (2.1%-15.8%)) ancestries, as previously suggested⁴⁹.

311 Estimated penetrance of individual rare variants

Of the variants identified and used to estimate penetrance in aggregate, we report four subgroups of variants in our case series (**Figure 3**):

314 Group 1 consisted of 339 variants that were found in more than one case (case allele 315 count (AC) \geq 2) and were ultra-rare in population reference sets (population AC (popAC)) 316 \leq 1). Penetrance cannot be estimated with precision for individual variants in this group, 317 since the population allele frequency (AF) cannot be estimated with precision. When 318 considered in aggregate this group have high penetrance (Figures S14). For HCM, 294 319 variants in group 1 were identified 1.322 times (13% case frequency, 31% 320 observations). 29% were curated as pathogenic (P, n=84, 41% of HCM group 1 321 observations), 34% were likely pathogenic (LP, n=100, 36% observations), and 37% 322 were curated as uncertain significance (VUS, n=110, 23% observations). For DCM, 45 323 variants in group 1 were identified 132 times (5% case frequency, 16% observations). 324 18% of these were P (n=8, 20% DCM group 1 observations), 49% LP (n=22, 55% 325 observations), and 33% VUS (n=15, 25% observations).

326 Group 2 included 316 variants found multiple times in both cases and population 327 reference datasets (caseAC \geq 2, popAC \geq 2). This group is expected to include variants 328 with intermediate penetrance, including founder effect variants. For this group, we can 329 estimate AF in both populations, and therefore can estimate penetrance (Figure 4, 330 Interactive Figure 4, Tables S10-S11). These account for more than half of all variants identified in HCM-associated genes and include those most likely to be identified as 331 332 SFs. For HCM, 257 variants were identified a total of 2,203 times (21% case frequency, 333 51% observations). 11% were P (n=29, 37% HCM group 2 observations), 25% LP 334 (n=64, 31% observations), 59% VUS (n=151, 29% observations), and 5% likely benign 335 (LB, n=13, 3% observations). 49 of these variants were recurrent at least ten times and 336 described a large portion of observations (case AC≥10; found 1.424 times, 33.0% of 337 case cohort observations, case frequency of 13.7%). The median penetrance of these 338 was 14.6% (±14.4% SD). For DCM, 59 variants were identified 140 times (6% case 339 frequency, 17% observations). None were curated as P, 24% were LP (n=14, 22% DCM 340 group 2 observations), 56% VUS (n=33, 53% observations), 17% LB (n=10, 21% 341 observations), and 3% B (n=2, 4% observations). With the current DCM case cohort 342 size, no variant was identified ten or more times.

343 The final two groups consisted of 1,350 variants with only a single observation in our 344 case series. This does not provide a reliable of case frequency so penetrance estimates 345 would lack precision. Group 3 variants were those identified multiple times in the 346 population (popAC≥2), and consisted mostly of VUSs: For HCM, 206 variants were 347 identified (2% case frequency, 5% of case observations). This included 0.5% P (n=1; 348 MYBPC3:c.3297dup:p.(Tyr1100Valfs*49)), 5% LP (n=10), 92% VUS (n=189), and 3% 349 LB (n=6). For DCM, 232 variants were identified (9% case frequency, 28% 350 observations). 1% were P (n=3), 7% LP (n=17), 79% VUS (n=183), 12% LB (n=27), and 351 1% B (n=2).

Group 4 variants are those observed once in cases, and rarely in the population reference dataset (popAC \leq 1). A substantial portion of these were P/LP: for HCM, 583 variants were identified (6% case frequency, 13% observations). 10% were P (n=59), 24% LP (n=142), and 66% VUS (n=382). For DCM, 329 variants were identified (13% case frequency, 40% observations). 3% were P (n=10), 58% LP (n=192), and 39% VUS (n=127).

358 The impact of age, sex, and ancestry, on variant-specific penetrance estimates

For group 2, where age-related penetrance could be derived, we estimated the penetrance of specific variants by decade of age (e.g., **Figure 5**). For some variants (e.g., MYBPC3:c.1624G>C:p.(Glu542Gln)), the age-related penetrance curve shows infrequent onset before middle age. These curves may inform surveillance strategies in variant carriers unaffected at first assessment.

- We identified rare variants in HCM-associated genes where estimated penetrance for males was significantly increased compared to females (**Figure S13**). Identification of such variants allows for future investigations of modifiers protecting female carriers from disease.
- 368 For estimates of penetrance by ancestry, variants that were nominally more common in 369 AFR, EAS, or SAS ancestries compared to EUR ancestry were identified (Table S12). 370 We interpret these as more consistent with inaccurate penetrance estimation arising 371 from ancestries where the variant is sparsely observed, rather than true differences in 372 different penetrance on ancestral background. For example, 373 MYBPC3:c.1544A>G:p.(Asn515Ser) was identified 5/492 times in AFR cases 374 (AF=0.005) and 33/10,655 times in the AFR population participants (AF=0.0016; 375 penetrance of 0.6% (0.2%-1.5%)) compared to 1/9,692 times in EUR cases 376 (AF=0.00005) and not observed in 211,532 EUR population participants. Even when 377 ancestry is nominally matched, broad continental groupings hide great diversity and 378 results may be misleading due to stratification between cases datasets (mostly North 379 AFR from Egypt) and population reference datasets (e.g., UK Biobank participants from 380 the Caribbean) (**Box 1**).
- 381 Clinical impact of specific variants now shown to have low penetrance
- We can define the upper bound of the penetrance estimate for some variants. 162 rare variants in HCM-associated genes (63% of variants, observed 745 times (7% case frequency; 17% of observations) have a penetrance of \leq 10%, according to the upper limit (UCI) of the 95% CI for our estimate. These included two variants previously curated as definitively pathogenic, and 25 variants curated as likely pathogenic.
- 387

One of the pathogenic variants is splice acceptor MYBPC3:c.26-2A>G which has an estimated penetrance of 1.0% (0.4%-2.8%) or 0.9% (0.3%-2.5%) in EUR ancestry, as it was identified 4 times in EUR cases and 20 times in population participants (90% were EUR). The potential for this variant to have incomplete penetrance has been noted previously through identified asymptomatic carriers (see ClinVar ID 42644). There is in

silico evidence of an alternate splice site downstream that could result in an in-framedeletion of two amino acids.

395

The second pathogenic variant identified with a UCI of $\leq 10\%$ is the missense variant MYH7:c.3158G>A:p.R1053Q which is a Finnish founder mutation. This variant had an estimate penetrance of 2.2% (0.9%-5.2%), as it was identified 7 times in EUR cases and 17 times in the population cohort (16 Finnish from gnomAD, 1 NWE from UK Biobank). Estimates of penetrance are sensitive to allele frequency differences across ancestries. Analysis of founder mutations in the population they derive from would provide additional confidence in their penetrance estimates.

403

404 For DCM, 17 rare variants (29% of variants) observed 45 times (2% case frequency; 5%
405 of observations) met this criterion. None of the 17 variants were curated as P/LP.

406

Box 1

407 Case study: The MYBPC3:c.1504C>T:p.(Arg502Trp) Northwestern European variant

The variant MYBPC3:c.1504C>T:p.R502W was found in our cohort 159 times in patients referred for HCM genetic panel sequencing (3.7% of total observations; 1.5% total case frequency). To date, the variant has been classified on ClinVar fifteen times as pathogenic (ClinVar ID 42540). Penetrance has been previously estimated as ~50% (increased relative risk of 340) by 45 years old in a clinical setting, with major adverse clinical events in carriers significantly more likely when another sarcomeric variant is present⁵⁰.

415

416 In our case cohort, carriers of this variant were reported as broadly European ancestry 417 (Oxford, n=59; London, n=11; Belfast, n=30; LMM, n=45; GDX, n=14). In gnomAD, the 418 variant was identified 10 times, of which 7 carriers were non-Finnish Northwestern 419 Europeans (NWE; plus 1 African; 1 South Asian, and 1 other), and in the UK Biobank, 420 the variant was found 77 times, of which 68 carriers were NWE (plus 8 other 421 Europeans, and 1 other). The population frequency of the variant in Ensembl population 422 genetics showed that the variant (rs375882485) is only found multiple times in NWE 423 ancestry sub cohorts. Thus, the variant is most common in NWE populations: the UK, 424 Ireland, Belgium, the Netherlands, Luxembourg, Northern France, Germany, Denmark, 425 Norway, Sweden, and Iceland.

426

We use this relatively common variant to highlight the effect of ancestry on estimated variant penetrance (**Figure 6**): the penetrance was estimated as 6.4% (4.6%-9.0%) using the UK Biobank cohort (93% European) and this is inflated to 35.1% (18.2%-67.5%) when estimating the penetrance using the gnomAD dataset (45% European), due to the difference in the proportion of individuals with NWE ancestry. In individuals of NWE ancestry only, the penetrance of this variant is 6.4% (4.6%-9.0%). Penetrance estimated from the NWE subset of gnomAD or UKB do not differ significantly.

434

As access to larger genomic datasets becomes available, including more diverse
ancestries, we can increase the precision of these variant-specific penetrance estimates
by gaining further confidence in maximum population allele frequencies⁵¹.

- [end of box 1]
- 438 439

440 Penetrance estimate simulations of increased cohort sizes

We anticipate two benefits to estimating the penetrance of rare variants from increasing cohort sizes: i) there will be more variants that are observed recurrently in cases and populations, permitting AF estimates and hence penetrance estimates, and ii) the precision of our penetrance estimates will increase as AF of rare variants is ascertained with greater precision.

We sought to understand whether it would be more valuable to focus resources on aggregating data from larger numbers of cases (plausible ~100,000 cases with global collaboration efforts), and/or from larger numbers of population participants with nearterm publicly available population datasets (~5,000,000 participants).

450 Efforts to increase reference population sample size will provide additional confidence in 451 penetrance estimates once case aggregation to 10,000 cases is reached (Figure S6). 452 There is substantial confidence to be gained by increasing the population cohort size: 453 we found that increasing the population dataset from 300,000 participants to 4.5 million 454 participants could provide ~20% certainty, depending on the penetrance of the variant 455 (Figures S7-S11). The increase in confidence gained from increasing the case cohort sample size from 10,000 cases to 100,000 cases was limited (with the caveat that more 456 457 variants will be identified).

458 Discussion

459

We show that some subgroups of rare variants in the population are penetrant and for these it may be reasonable to return as SFs. These include ultra-rare variants, predicted PTCs in certain genes where loss of function is a known disease mechanism, and variants with enough evidence to have been classified as definitively pathogenic previously (**Graphical abstract**).

465

There is still uncertainty regarding the penetrance of individual ultra-rare variants, and the implications of returning SFs in healthcare systems have yet to be estimated. While we have previously attempted to assess the burden of long-term surveillance for DCM⁶, cost-effect analyses are vital to fully understand the risks and benefits of reporting SFs in different healthcare systems. For variant types with low penetrance, it is very uncertain that the benefit of returning SFs will outweigh harms and justify costs.

472

Here, we provide the first at-scale estimates of variant-specific penetrance for variants
in CM-associated genes that include those likely to be most frequently identified as SFs.
Most have low estimated penetrance, where an asymptomatic individual without family
history for disease may choose no or less frequent surveillance, depending on the
healthcare system and follow-up cost.

478

Population penetrance estimates derived from unselected individuals (with certain caveats⁵²) that are agnostic to personal or family history of disease, should provide a better estimate of the probability of manifesting disease when a variant is identified as a SF. Importantly, the penetrance of variants found in CM patients and relatives in a clinical setting is increased compared to the penetrance of variants estimated for those identified through SFs (e.g., MYBPC3:c.1504C>T:p.R502W with estimated penetrance of 50% in HCM patients and 6% here, in the population).

486

487 While published data is sparse and heterogeneous, overall estimates of penetrance by 488 adulthood in the general population are lower than family-based studies. An abstract 489 reported the penetrance of asymptomatic carriers referred to hospital for predictive testing after identification of a genotype- and CM-positive relative⁵³. For HCM, 17 of 65 490 491 carriers (26.2%) were diagnosed with HCM (10 on first clinical evaluation, 7 during 2 492 years of follow up). For DCM, 2 of 22 carriers (9.1%) were diagnosed with DCM (2 on 493 first clinical evaluation, 0 during 2 years of follow up (excluding 5 with hypokinetic nondilated cardiomyopathy and 4 with isolated left ventricular dilatation))⁵³. Additionally, a 494 495 study of carriers identified during family screening who did not fulfill diagnostic criteria 496 for HCM at first evaluation identified HCM or an abnormal ECG in 127 of 285 carriers (44.6%; 82 at baseline, 45 over a median of 8 years follow-up)²⁵. First degree relatives 497 498 in the same household may be at increased risk of disease due to shared environment 499 and other genetic factors.

500

501 The ACMG guidelines for reporting "medically actionable" variants in 78 genes come 502 with the caution that evaluating SFs requires an increased amount of supportive 503 evidence of pathogenicity, given the low prior likelihood that variants unrelated to the

504 indication are pathogenic⁵⁴. Here, we show that variants with a definitive pathogenic 505 assertion in ClinVar had the highest penetrance estimates. This may be because 506 penetrant variants are more likely to yield sufficient evidence for confident 507 interpretations, especially family segregation data.

509 Genetic laboratories communicate their confidence on whether a variant has a role in 510 disease (i.e., pathogenicity), but do not consistently indicate the penetrance. 511 Pathogenicity addresses whether a variant explains the aetiology of a patient. 512 Penetrance addresses the probability of future disease in carriers. The ClinGen 513 consortium Low-Penetrance/Risk Allele Working Group recommends providing 514 penetrance estimates on clinical reports (aggregate gene-level or individual variants) 515 and noting when penetrance is assumed or where current information is 516 limited/unavailable.

517

508

518 TTNtv are common in the general population (~1 in 250 for variants in exons 519 constitutively expressed in the adult heart), and we show that the penetrance in 520 aggregate of TTNtvs is reduced compared to predicted loss of function variants in other 521 CM-associated, haploinsufficient genes. While recent work has increased our 522 understanding of the functional mechanisms of TTNtvs in disease^{55,56}, future work is 523 required to identify modifiers of TTNtvs to understand this reduced penetrance in the 524 population.

525

526 The penetrance of a variant may depend on characteristics of the variant itself and 527 modulating effects of genetic background and environment. This study characterises 528 individual variants, while ongoing work is dissecting the role of secondary genetic 529 influences. Polygenic scores may identify individuals at particular risk of disease, 530 modifying the estimated penetrance of a single dominant variant.

531

532 We present two novel dimensions to estimates of penetrance: the penetrance in the 533 general population and variant-specific penetrance. As described, the results of this method are concordant with previous population estimates of aggregated penetrance in 534 535 the UKBB population derived using independent approaches, providing confidence in 536 the methods. In addition, we provide updated estimates for the population prevalence of 537 HCM and DCM and stratify by sex. The addition of future, publicly available, large-scale, 538 global population datasets and biobanks will aid this area of research by allowing for 539 increased confidence in ancestry-specific population allele frequencies and CM 540 prevalence. We provide the summary counts for each variant via an online browser and 541 the function to estimate penetrance in R for transferability and use in other diseases and 542 datasets.

543 Limitations

544 This study has not been undertaken without careful consideration of the limitations. This 545 method cannot quantify the penetrance of pathogenic variants that are absent/singleton 546 in the population, while in aggregate the penetrance of this group of variants is 547 significant. 548 Comparisons of case and control allele frequency are vulnerable to confounding by 549 population stratification, and we have explored some examples in this manuscript. We 550 do not have genome-wide variation data to directly assess genetic ancestry for the case 551 cohort, so this is based on data reported by the referring clinician. As the EUR 552 participants dominate our case and population datasets, greater representation of 553 diverse ancestral backgrounds is essential for equitable access to genomic medicine. 554 Estimates of the penetrance of variants and the prevalence of cardiomyopathies in more 555 ancestral groups are required. The current data for both comes from UK Biobank which 556 has limitations⁵².

- 557 In the absence of genome-wide data we cannot exclude the possibility of unrecognised 558 or cryptic relatedness within the case cohort. As described by Minikel et al. (2016)²⁶, 559 when a variant is highly penetrant, cryptically related individuals are likely included in 560 case series and if a disease is fatal, population cohorts are likely depleted of causal 561 variants.
- 562 Case allele frequency in unrelated cases may not be a fair estimate of the case allele 563 frequency in all cases observed in the clinic. Our estimate of case allele frequency, and 564 therefore of penetrance, is influenced by genetic testing referral practice. If clinicians are 565 cautious and only refer selected high confidence cases for testing, case allele frequency 566 and estimated penetrance will be high, whereas if clinicians were to test widely and 567 indiscriminately then our apparent case allele frequency would be lower, resulting in 568 lower penetrance estimates¹⁸.
- 569 Current diagnostic data assumes that the testing centre obtained complete coverage of 570 the gene. Limited data was available on age and sex for large portions of the case 571 cohorts. Our DCM referred cohort was only moderate in size and thus, increases in 572 sample size here through global collaboration would aid our estimates of penetrance for 573 variants in DCM-associated genes.
- 574 Finally, the UKBB volunteer population cohort is healthier than the average individual⁵², 575 and the gnomAD consortium includes some individuals with severe disease but likely at 576 a frequency equivalent to or lower than the general population³⁰. The proposed 577 penetrance model is an approximation since in reality the three parameters used on the 578 right-hand side of the penetrance equation share some degree of dependence.

579 **Conclusion**

580 This is the first evaluation of the penetrance of individual rare variants in CM-associated 581 genes at scale. These recurrent variants are those that are likely to generate SFs. 582 Variants previously annotated as pathogenic, loss-of-function variants in specific genes 583 susceptible to haploinsufficiency, and those that are the rarest in the population, have 584 high penetrance, similar to observations from family studies. This first attempt at 585 estimating the penetrance of rare variants has highlighted the requirement for large 586 case and population datasets with known genetic ancestry. We are now able to start 587 putting bounds on the estimate of penetrance for a specific variant identified as a

secondary finding: for some, including those expected to be most penetrant, we do not
currently have enough data, for others, we can provide asymptomatic variant carriers
with an estimated probability of manifesting disease.

591 Data and code availability

592 All case cohort data arising from this analysis is available through DECIPHER 593 (https://www.deciphergenomics.org/). Both gnomAD (https://gnomad.broadinstitute.org/) 594 and UK Biobank (https://www.ukbiobank.ac.uk/) population reference datasets are 595 code publicly available. Analysis is available on GitHub 596 (https://github.com/ImperialCardioGenetics/variantfx/tree/main/PenetrancePaper).

597 **Competing interests**

J.S.W. has consulted for MyoKardia, Inc., Foresite Labs, and Pfizer. A.H. now works for
AstraZeneca, UK. D.P.O. has consulted for Bayer. L.B. has consulted for Roche.
D.G.M. is a paid advisor to GlaxoSmithKline, Insitro, Variant Bio and Overtone
Therapeutics, and has received research support from AbbVie, Astellas, Biogen,
BioMarin, Eisai, Merck, Pfizer, and Sanofi-Genzyme; none of these activities are directly
related to the work presented here.

604 Acknowledgements and funding sources

This work was supported by the Wellcome Trust [107469/Z/15/Z; 200990/A/16/Z], Medical Research Council (UK) [MC_UP_1605/13], British Heart Foundation [RG/19/6/34387, RE/18/4/34215, FS/IPBSRF/22/27059], and the NIHR Imperial College Biomedical Research Centre. The views expressed in this work are those of the authors and not necessarily those of the funders. For open access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

612 **CrediT statement**

Conceptualization: J.S.W, K.A.M.; Methodology: J.S.W., K.A.M., L.B., X.Z., P.T.; Formal
Analysis: K.A.M., L.B., P.T., K.T., A.H.; Resources: K.T., R.B., W.T.W., D.M., P.C.J.,
B.F., D.M., S.P., S.C., M.A., Y.A., M.H.Y., D.O'R., H.W., J.SW.; Data curation: K.A.M.,
P.T., E.M.; Writing – original draft: K.A.M.; Writing – review & editing: (all authors);
Visualization: K.A.M., J.S.W.; Supervision: J.S.W., H.W.; Project administration: J.S.W.,
P.B.

619 **Ethics declaration**

620 All research participants provided written informed consent, and the studies were 621 reviewed and approved by the relevant research ethics committee (Aswan Heart 622 Centre: FWA00019142, Research Ethics Committee code 623 20130405MYFAHC_CMR_20130330; NIHR Royal Brompton Biobank: South Central -624 Hampshire B Research Ethics Committee, 09/H0504/104+5, 19/SC/0257; National 625 Heart Centre Singapore: Singhealth Centralised Institutional Review Board 2020/2353 626 and Singhealth Biobank Research Scientific Advisory Executive Committee SBRSA 627 2019/001v1: UK Biobank: National Research Ethics Service 11/NW/0382, 21/NW/0157. 628 under terms of access approval number 47602).

In addition, diagnostic laboratories (Oxford Molecular Genetics Laboratory, Belfast
 Regional Genetics Laboratory, the Partners Laboratory of Molecular Medicine, and

GeneDx) provided aggregated (and therefore fully anonymous) cohort-level summaries
of variant data collected for clinical purposes during routine healthcare. Secondary use
of this data did not require research consent from individuals, and approval for public
release of the data followed local governance procedures. Data are publicly available,
through DECIPHER (https://www.deciphergenomics.org/). Analyses of these data do
not require Research Ethics Committee approval.

637 **References**

Blout Zawatsky, C.L., Bick, D., Bier, L., Funke, B., Lebo, M., Lewis, K.L., Orlova, E.,
Qian, E., Ryan, L., Schwartz, M.L.B., et al. (2023). Elective genomic testing: Practice

- 640 resource of the National Society of Genetic Counselors. J. Genet. Couns.
- 641 2. Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K.,
- 642 Gollob, M.H., Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2022). ACMG SF
- v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A
- 644 policy statement of the American College of Medical Genetics and Genomics (ACMG).
- 645 Genet. Med. 24, 1407–1414.
- 646 3. Wilde, A.A.M., Semsarian, C., Márquez, M.F., Shamloo, A.S., Ackerman, M.J.,
- 647 Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al.
- 648 (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia
- 649 Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS)
- 650 Expert Consensus Statement on the state of genetic testing for cardiac diseases . EP
- 651 Eur. 24, 1307–1367.
- 4. de Wert, G., Dondorp, W., Clarke, A., Dequeker, E.M.C., Cordier, C., Deans, Z., van
- 653 EI, C.G., Fellmann, F., Hastings, R., Hentze, S., et al. (2021). Opportunistic genomic 654 screening. Recommendations of the European Society of Human Genetics. Eur. J.
- 655 Hum. Genet. 29, 365–377.
- 5. Ormondroyd, E., Mackley, M.P., Blair, E., Craft, J., Knight, J.C., Taylor, J.C., Taylor,
 J., and Watkins, H. (2018). "Not pathogenic until proven otherwise": Perspectives of UK
 clinical genomics professionals toward secondary findings in context of a Genomic
 Medicine Multidisciplinary Team and the 100,000 Genomes Project. Genet. Med. *20*,
 320–328.
- 6. McGurk, K.A., Zheng, S.L., Henry, A., Josephs, K., Edwards, M., de Marvao, A.,
 Whiffin, N., Roberts, A., Lumbers, T.R., O'Regan, D.P., et al. (2022). Correspondence
 on "ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome
 sequencing: a policy statement of the American College of Medical Genetics and
 Genomics. Genet. Med. *24*, 744–746.
- 7. Wilson, J.M.G., and Jungner, G. (1968). Principles and practice of screening fordisease: public health papers no. 34 (Geneva: World Health Organization).
- 668 8. Wynn, J., Martinez, J., Bulafka, J., Duong, J., Zhang, Y., Chiuzan, C., Preti, J.,
- 669 Cremona, M.L., Jobanputra, V., Fyer, A.J., et al. (2018). Impact of Receiving Secondary
- Results from Genomic Research: A 12-Month Longitudinal Study. J. Genet. Couns. 27,
 709–722.
- 9. Hart, M.R., Biesecker, B.B., Blout, C.L., Christensen, K.D., Amendola, L.M.,
- 673 Bergstrom, K.L., Biswas, S., Bowling, K.M., Brothers, K.B., Conlin, L.K., et al. (2019).
- 674 Secondary findings from clinical genomic sequencing: prevalence, patient perspectives,
- 675 family history assessment, and health-care costs from a multisite study. Genet. Med.
- 676 Off. J. Am. Coll. Med. Genet. 21, 1100–1110.
- 10. Thauvin-Robinet, C., Thevenon, J., Nambot, S., Delanne, J., Kuentz, P., Bruel, A.-

- L., Chassagne, A., Cretin, E., Pelissier, A., Peyron, C., et al. (2019). Secondary
- 679 actionable findings identified by exome sequencing: expected impact on the
- organisation of care from the study of 700 consecutive tests. Eur. J. Hum. Genet. *27*,
 1197–1214.
- 11. Mackley, M.P., Fletcher, B., Parker, M., Watkins, H., and Ormondroyd, E. (2017).
- Stakeholder views on secondary findings in whole-genome and whole-exome
 sequencing: A systematic review of quantitative and qualitative studies. Genet. Med. *19*,
- 685 283–293.
- 12. Ormondroyd, E., Harper, A.R., Thomson, K.L., Mackley, M.P., Martin, J., Penkett,
 C.J., Salatino, S., Stark, H., Stephens, J., and Watkins, H. (2020). Secondary findings in
 inherited heart conditions: a genotype-first feasibility study to assess phenotype,
 behavioural and psychosocial outcomes. Eur. J. Hum. Genet. *28*, 1486–1496.
- 13. de Marvao, A., McGurk, K.A., Zheng, S.L., Thanaj, M., Bai, W., Duan, J., Biffi, C.,
- Mazzarotto, F., Statton, B., Dawes, T.J.W., et al. (2021). Phenotypic Expression and
 Outcomes in Individuals With Rare Genetic Variants of Hypertrophic Cardiomyopathy. J.
 Am. Coll. Cardiol. *78*, 1097–1110.
- 14. Pirruccello, J.P., Bick, A., Wang, M., Chaffin, M., Friedman, S., Yao, J., Guo, X.,
 Venkatesh, B.A., Taylor, K.D., Post, W.S., et al. (2020). Analysis of cardiac magnetic
 resonance imaging in 36,000 individuals yields genetic insights into dilated
 cardiomyopathy. Nat. Commun. *11*, 2254.
- 15. Pirruccello, J.P., Bick, A., Chaffin, M., Krishna, G., Choi, S.H., Lubitz, S.A., Carolyn,
 Y., Ng, K., Philippakis, A., Ellinor, P.T., et al. (2021). Titin truncating variants in adults
 without known congestive heart failure. J. Am. Coll. Cardiol. *75*, 1239–1241.
- 16. Castel, S.E., Cervera, A., Mohammadi, P., Aguet, F., Reverter, F., Wolman, A.,
- Guigo, R., Iossifov, I., Vasileva, A., and Lappalainen, T. (2018). Modified penetrance of
 coding variants by cis-regulatory variation contributes to disease risk. Nat. Genet. *50*,
 1327–1334.
- 17. Goodrich, J.K., Singer-Berk, M., Son, R., Sveden, A., Wood, J., England, E., Cole,
- J.B., Weisburd, B., Watts, N., Caulkins, L., et al. (2021). Determinants of penetrance
- and variable expressivity in monogenic metabolic conditions across 77,184 exomes.Nat. Commun. *12*, 3505.
- 18. Kingdom, R., and Wright, C.F. (2022). Incomplete Penetrance and Variable
 Expressivity :: From Clinical Studies to Population Cohorts. Front. Genet. *13*, 920390.
- 711 19. Glazier, A.A., Thompson, A., and Day, S.M. (2019). Allelic imbalance and
- haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy. Pflügers Arch. Eur.
 J. Physiol. 471, 781–793.
- 20. Roberts, A.M., Ware, J.S., Herman, D.S., Schafer, S., Baksi, J., Bick, A.G., Buchan,
- 715 R.J., Walsh, R., John, S., Wilkinson, S., et al. (2015). Integrated allelic, transcriptional,
- and phenomic dissection of the cardiac effects of titin truncations in health and disease.
- 717 Sci. Transl. Med. 7, 270ra6.

- 718 21. Tadros, R., Francis, C., Xu, X., Vermeer, A.M.C., Harper, A.R., Huurman, R., Kelu
- Bisabu, K., Walsh, R., Hoorntje, E.T., te Rijdt, W.P., et al. (2021). Shared genetic
- pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite
- 721 directions of effect. Nat. Genet. 53, 128–134.
- 722 22. Harper, A.R., Goel, A., Grace, C., Thomson, K.L., Petersen, S.E., Xu, X., Waring,
- A., Ormondroyd, E., Kramer, C.M., Ho, C.Y., et al. (2021). Common genetic variants
- and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and
- 725 expressivity. Nat. Genet. *53*, 135–142.
- 726 23. McGurk, K.A., and Halliday, B.P. (2022). Dilated cardiomyopathy details make the
 727 difference. Eur. J. Heart Fail. *24*, 1197–1199.
- 728 24. Gail, M.H., Pee, D., Benichou, J., and Carroll, R. (1999). Designing studies to
- estimate the penetrance of an identified autosomal dominant mutation: Cohort, case-control, and genotyped-proband designs. Genet. Epidemiol. *16*, 15–39.
- 731 25. Lorenzini, M., Norrish, G., Field, E., Ochoa, J.P., Cicerchia, M., Akhtar, M.M., Syrris,
- 732 P., Lopes, L.R., Kaski, J.P., and Elliott, P.M. (2020). Penetrance of Hypertrophic
- Cardiomyopathy in Sarcomere Protein Mutation Carriers. J. Am. Coll. Cardiol. *76*, 550–559.
- 735 26. Minikel, E.V., Vallabh, S.M., Lek, M., Estrada, K., Samocha, K.E.,
- 736 Sathirapongsasuti, J.F., McLean, C.Y., Tung, J.Y., Yu, L.P.C., Gambetti, P., et al.
- 737 (2016). Quantifying prion disease penetrance using large population control cohorts.
 738 Sci. Transl. Med. *8*, 322ra9.
- 750 Sci. Hansi. Weu. 0, 522189.
- 739 27. Ackerman, M.J., Priori, S.G., Willems, S., Berul, C., Brugada, R., Calkins, H.,
- 740 Camm, A.J., Ellinor, P.T., Gollob, M., Hamilton, R., et al. (2011). HRS/EHRA Expert
- 741 Consensus Statement on the State of Genetic Testing for the Channelopathies and
- 742 Cardiomyopathies. EP Eur. *13*, 1077–1109.
- 28. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
 Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with
 deep phenotyping and genomic data. Nature *562*, 203–209.
- 746 29. Szustakowski, J.D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson, P.G.,
- Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, C., et al. (2021). Advancing
- human genetics research and drug discovery through exome sequencing of the UK
- 749 Biobank. Nat. Genet. 53, 942–948.
- 750 30. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q.,
- Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational
 constraint spectrum quantified from variation in 141,456 humans. Nature *581*, 434–443.
- 753 31. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek,
- P., and Cunningham, F. (2016). The Ensembl Variant Effect Predictor. Genome Biol.*17*, 122.
- 756 32. Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J.F., Darbandi, S.F., 757 Knowles, D., Li, Y.I., Kosmicki, J.A., Arbelaez, J., Cui, W., Schwartz, G.B., et al. (2019).

- 758 Predicting Splicing from Primary Sequence with Deep Learning. Cell *176*, 535–548.
- 33. Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti,
- 760 S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble
- 761 Method for Predicting the Pathogenicity of Rare Missense Variants. Am. J. Hum.
- 762 Genet. 99, 877–885.
- 763 34. Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M.,
- and Maglott, D.R. (2014). ClinVar: public archive of relationships among sequence
- variation and human phenotype. Nucleic Acids Res. *42*, D980-5.
- 766 35. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D.,
- 767 Maller, J., Sklar, P., de Bakker, P.I.W., Daly, M.J., et al. (2007). PLINK: a tool set for
- whole-genome association and population-based linkage analyses. Am. J. Hum.Genet. *81*, 559–575.
- 36. Ingles, J., Goldstein, J., Thaxton, C., Caleshu, C., Corty, E.W., Crowley, S.B.,
- Dougherty, K., Harrison, S.M., McGlaughon, J., Milko, L. V., et al. (2019). Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes. Circ. Genomic Precis. Med. *12*,
- 773 57–64.
- 37. Jordan, E., Peterson, L., Ai, T., Asatryan, B., Bronicki, L., Brown, E., Celeghin, R.,
- Edwards, M., Fan, J., Ingles, J., et al. (2021). Evidence-Based Assessment of Genes in
 Dilated Cardiomyopathy. Circulation *144*, 7–19.
- 38. Whiffin, N., Walsh, R., Govind, R., Edwards, M., Ahmad, M., Zhang, X., Tayal, U.,
- Buchan, R., Midwinter, W., Wilk, A.E., et al. (2018). CardioClassifier: disease- and
 gene-specific computational decision support for clinical genome interpretation. Genet.
 Med. *20*, 1246–1254.
- 781 39. Zou, Y., Song, L., Wang, Z., Ma, A., Liu, T., Gu, H., Lu, S., Wu, P., Zhang, Y., Shen,
- L., et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: A
- population-based echocardiographic analysis of 8080 adults. Am. J. Med. *116*, 14–18.
- 40. Maron, B.J., Spirito, P., Roman, M.J., Paranicas, M., Okin, P.M., Best, L.G., Lee,
- E.T., and Devereux, R.B. (2004). Prevalence of hypertrophic cardiomyopathy in a
- population-based sample of American Indians aged 51 to 77 years (the Strong HeartStudy). Am. J. Cardiol. *93*, 1510–1514.
- 41. Maron, B.J., Gardin, J.M., Flack, J.M., Gidding, S.S., Kurosaki, T.T., and Bild, D.E.
 (1995). Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young
 Adults. Circulation *92*, 785–789.
- 42. Petersen, S.E., Aung, N., Sanghvi, M.M., Zemrak, F., Fung, K., Paiva, J.M., Francis,
 J.M., Khanji, M.Y., Lukaschuk, E., Lee, A.M., et al. (2017). Reference ranges for cardiac
 structure and function using cardiovascular magnetic resonance (CMR) in Caucasians
- 794 from the UK Biobank population cohort. J. Cardiovasc. Magn. Reson. *19*, 18.
- 43. Mestroni, L., Maisch, B., McKenna, W.J., Schwartz, K., Charron, P., Rocco, C.,
- 796 Tesson, F., Richter, A., Wilke, A., and Komajda, M. (1999). Guidelines for the study of
- familial dilated cardiomyopathies. Collaborative Research Group of the European

- Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur. Heart J.
 20, 93–102.
- 44. McNally, E.M., and Mestroni, L. (2017). Dilated cardiomyopathy: Genetic determinants and mechanisms. Circ. Res. *121*, 731–748.
- 45. O'Malley, K.J., Cook, K.F., Price, M.D., Wildes, K.R., Hurdle, J.F., and Ashton, C.M. (2005). Measuring diagnoses: ICD code accuracy. Health Serv. Res. *40*, 1620–1639.
- 46. Hershberger, R.E., Hedges, D.J., and Morales, A. (2013). Dilated cardiomyopathy:
 The complexity of a diverse genetic architecture. Nat. Rev. Cardiol. *10*, 531–547.
- 47. Shah, R.A., Asatryan, B., Dabbagh, G.S., Aung, N., Khanji, M.Y., Lopes, L.R., van
 Duijvenboden, S., Holmes, A., Muser, D., Landstrom, A.P., et al. (2022). Frequency,
 Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative
 Pathogenic Gene Variants in UK Biobank Participants. Circulation *146*, 101–124.
- 48. Lindeboom, R.G.H., Supek, F., and Lehner, B. (2016). The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat. Genet. *48*, 1112–1118.
- 49. Haggerty, C.M., Damrauer, S.M., Levin, M.G., Birtwell, D., Carey, D.J., Golden,
- A.M., Hartzel, D.N., Hu, Y., Judy, R., Kelly, M.A., et al. (2019). Genomics-First
- Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation *140*,
 42–54.
- 50. Saltzman, A.J., Mancini-DiNardo, D., Li, C., Chung, W.K., Ho, C.Y., Hurst, S., Wynn,
 J., Care, M., Hamilton, R.M., Seidman, G.W., et al. (2010). Short communication: the
- 818 cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic 819 cardiomyopathy. Circ. Res. *106*, 1549–1552.
- 51. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y.,
- Barton, P.J.R., Funke, B., Cook, S.A., Macarthur, D., et al. (2017). Using high-resolution
 variant frequencies to empower clinical genome interpretation. Genet. Med. *19*, 1151–
 1158.
- 52. Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins,
- 825 R., and Allen, N.E. (2017). Comparison of Sociodemographic and Health-Related
- Characteristics of UK Biobank Participants With Those of the General Population. Am.J. Epidemiol. *186*, 1026–1034.
- 53. Mahmood, A., Morris-Rosendahl, D., Edwards, M., Fleming, A., Homfray, T., Mason,
 S., Quinn, E., Ware, J., Baksi, J., Prasad, S., et al. (2022). 10 Disease penetrance in
 asymptomatic carriers of familial cardiomyopathy variants. Heart *108*, A9 LP-A9.
- 831 54. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W.,
- Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the
- 833 interpretation of sequence variants: A joint consensus recommendation of the American
- 834 College of Medical Genetics and Genomics and the Association for Molecular
- 835 Pathology. Genet. Med. 17, 405–424.
- 55. McAfee, Q., Chen, C.Y., Yang, Y., Caporizzo, M.A., Morley, M., Babu, A., Jeong, S.,
 Brandimarto, J., Bedi, K.C., Flam, E., et al. (2022). Truncated titin proteins in dilated

- 838 cardiomyopathy. Sci. Transl. Med. 13, eabd7287.
- 839 56. Fomin, A., Gärtner, A., Cyganek, L., Tiburcy, M., Tuleta, I., Wellers, L., Folsche, L.,
- Hobbach, A.J., von Frieling-Salewsky, M., Unger, A., et al. (2022). Truncated titin
- 841 proteins and titin haploinsufficiency are targets for functional recovery in human
- cardiomyopathy due to TTN mutations. Sci. Transl. Med. 13, eabd3079.

843

844 Figure legends

- 845
- 846

Figure 1 Aggregated penetrance of rare variants by variant curation, rarity, age, andsex.

849 In aggregate, variants curated as pathogenic and variants that are particularly rare 850 (gnomAD AC=0) were most penetrant. The plot depicts aggregated estimated penetrance for rare variants in HCM- (A, B, C, D) and DCM-associated (E, F, G, H) 851 852 genes. Variant curation was assessed following ACMG guidelines through ClinVar and 853 CardioClassifier software with additional manual curation of variants with conflicting 854 evidence (A, E (for HCM cases: 173 P variants, 316 LP, 832 VUS, 19 LB; for the UK 855 Biobank: 30 P, 98 LP, 1552 VUS, 53 LB, 2 B; for DCM cases: 21 P, 245 LP, 358 VUS, 856 37 LB, 4 B; for the UK Biobank: 15 P, 505 LP, 3951 VUS, 108 LB, 7 B)). The variants 857 were assessed for rarity by gnomAD allele count (AC) bins, where 0 is not identified in 858 the gnomAD dataset (B, F). Age was assessed in decades based on the cumulative 859 proportion of cases analysed by each age timepoint (C, G). Sex was estimated using all 860 parameters stratified by reported sex (D, H).

861

Figure 2 The aggregate estimates of penetrance of "loss of function" variants are highfor specific genes.

The plot depicts estimated penetrance of HCM-associated (left) and DCM-associated (right) rare variants. pLoF and non-pLoF variant groups are plotted in green and blue, respectively. pLoF, predicted loss of function variants; *, TTNtv that are PSI>90%. Pathogenic *TNNT2* inframe deletions caused an increased penetrance signal for inframe deletions for both HCM and DCM (see **Figure S12**).

869

Figure 3 Penetrance of individual variants could be estimated for 316 recurrently

observed rare variants from group 2.

The figure shows variant counts and subgroups for rare variants in HCM-associated (left) and DCM-associated (right) genes. The colour of the description matches the subgroup of variants depicted. The pie charts plot the proportion of all variant observations in each subgroup (also denoted as 'G+'). The observations approximate to the number of variant carriers, though a small number of individuals may carry more than one variant. G+, denotes the proportion of all variants identified; all, frequency of the variant in cases; obs, observations of allele count.

879

Figure 4 Variant-specific estimates of penetrance for the 316 recurrently observed rare variants in CM-associated genes from group 2.

An interactive widget is available for browsing the individual variants in this figure (**see Figure4_interactive.html**). The variants depicted (HCM n=257 (top), DCM n=59 (bottom)) were identified multiple times in cases and population reference datasets and penetrance could therefore be estimated. The x-axis denotes the number of times the variant was observed in each case cohort. AC, allele count; B/LB, benign/likely benign; VUS, variant of uncertain significance; LP, likely pathogenic; P, pathogenic.

888


Figure 5 Variant-specific estimates of penetrance by age can now be derived.


The plot depicts the age-related cumulative penetrance of five HCM-associated rare variants across age deciles from variant group 2. The x-axis starts in the decade of the 20s as the analysis of these variants was underpowered for teens and younger. "20s" here means "by 30 years old".


894


Figure 6 Penetrance estimates are inflated with underestimated population frequency.


896 The map of the world emphasises the large proportion of observations of 897 *MYBPC3*:c.1504C>T:p.(Arg502Trp) in HCM cases of Northwestern European (NWE) 898 ancestry. The numbers on the map are the counts of rare variant genotype positive 899 observations (n≈cohort participants) from each cohort with the specified ancestry, and 900 the percentages derive the proportion of observations that are due to the 901 MYBPC3:c.1504C>T:p.(Arg502Trp) variant. The graph shows the penetrance estimated 902 for the variant based on subgroups of reference dataset participants included. The 903 penetrance is inflated when estimated using gnomAD due to the variant being most 904 common in participants with NWE ancestry (which dominates the UKBB dataset). 905 Population frequency of gnomAD, UK Biobank, and Ensembl population genetics 906 showed that this variant (rs375882485) is only found multiple times in NWE ancestry 907 sub cohorts. The map excludes Antarctica for figure clarity. A limitation is the low 908 sample sizes for AFR, SAS, and EAS, ancestries.

















- **Group1**: Variants observed recurrently in cases and absent or singleton in the population: penetrance estimates are unreliable as the population frequency is uncertain. This group is expected to include most definitively pathogenic, high penetrance variants.
- Group 2*: Variants observed recurrently in cases and the wider population: these are the variants most likely to be observed as secondary findings. *Penetrance can be estimated.
- Group 3: Variants observed once in cases, and recurrently in the population: penetrance estimates are unreliable as the case frequency is uncertain. Variants in this group are likely either not pathogenic or have low penetrance.
- Group 4: Variants are singleton in cases and absent or singleton in the population: current data is too sparse to estimate penetrance.









MYBPC3:c.1624G>C:p.E542Q

